All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is a pharmaceutical reporter for the Clinical Trials Arena. Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Abigail has an expertise in trial design, cell and gene therapies and neurodegenerative diseases. Contact Abigail

Pharma and medtech industry reacts to FDA, CDC and NIH job cuts

Figures from across the pharmaceutical and medtech industry have spoken out on social media following the culling of staff at…
OCT West Coast 2025: China surpasses US for annual number of clinical trials

China has seen a rise in ongoing clinical trials for the past few years which has now surpassed the US,…
Be realistic, responsive and transparent: how to engage underperforming sites

Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that was the takeaway from…
RFK Jr. thrusts domestic manufacturing agenda on Day 2 of confirmation hearings

Robert F. Kennedy Jr. (RFK Jr) has claimed that “China will be able to ransom medical health” in America due…
OCT West Coast 2025: Efficient trials will help at all levels

Small and medium-sized enterprises are always looking for ways to run effective trials at a reasonable cost. It has become…

Trump signs executive order to leave World Health Organization

President Donald Trump has signed an executive order for the US to leave the World Health Organization (WHO). As one…
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD)…
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance

Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting…
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo

Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR)…
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit

AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…